StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.26 | $1.30 | +3.17% | 0.9M |
| 05-12 | $1.29 | $1.29 | +0.00% | 0.3M |
| 05-13 | $1.28 | $1.33 | +3.91% | 0.3M |
| 05-14 | $1.31 | $1.34 | +2.29% | 0.4M |
| 05-15 | $1.33 | $1.27 | -4.51% | 0.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $20.59M | $90.50M | $67.90M | $46.40M |
Operating Income | $-12.96M | $-53.66M | $-43.76M | $-29.37M |
Net Income | $-13.65M | $-54.00M | $-43.58M | $-15.17M |
EPS (Diluted) | $-0.33 | $-1.33 | $-1.08 | $-0.74 |
Total Assets | $119.97M | $129.29M | $138.28M | $147.19M |
Total Liabilities | $74.20M | $75.17M | $78.25M | $78.10M |
Cash & Equivalents | $61.57M | $69.75M | $76.55M | $75.47M |
Free Cash Flow OCF − CapEx | $-10.11M | $-32.83M | $-25.73M | $-17.48M |
Shares Outstanding | 42.24M | 41.67M | 41.25M | 40.74M |